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Abstract
Background: Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying
ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing
discordances between FISH and IHC. The controversy is further fuelled by the different regulatory approvals. This situation
prompted us to investigate two ALK IHC antibodies (using a novel ultrasensitive detection-amplification kit) and an
automated ALK FISH scanning system (FDA-cleared) in a series of non-small cell lung cancer tumor samples.
Methods: Forty-seven ALK FISH-positive and 56 ALK FISH-negative NSCLC samples were studied. All specimens were
screened for ALK expression by two IHC antibodies (clone 5A4 from Novocastra and clone D5F3 from Ventana) and for ALK
rearrangement by FISH (Vysis ALK FISH break-apart kit), which was automatically captured and scored by using Bioview’s
automated scanning system.
Results: All positive cases with the IHC antibodies were FISH-positive. There was only one IHC-negative case with both
antibodies which showed a FISH-positive result. The overall sensitivity and specificity of the IHC in comparison with FISH
were 98% and 100%, respectively.
Conclusions: The specificity of these ultrasensitive IHC assays may obviate the need for FISH confirmation in positive IHC
cases. However, the likelihood of false negative IHC results strengthens the case for FISH testing, at least in some situations.
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Introduction
In August 2011, crizotinib, a novel ALK tyrosine kinase
inhibitor, was approved by the US FDA for the treatment of
patients with locally advanced or metastatic non-small-cell lung
carcinomas (NSCLCs) that are ALK-positive as detected by an
FDA-approved test (i.e. Vysis ALK FISH Break-Apart Probe Kit)
[1]. Soon afterwards, the drug was approved by the EMA, with the
statement that ‘‘an accurate and validated ALK assay is necessary
for the selection of patients’’ [2]. Based on these excellent results of
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the crizotinib clinical trials and the development of other ALK
inhibitors with consistent efficacy results in this patient population,
the importance of accurately identifying ALK positive lung cancer
has never been greater [3].
Few areas in cancer biomarkers have been as contentious as
HER2 testing in breast cancer patients. Since 1998, we have
witnessed a huge clinical advance in this field and, however, a
great biomarker conundrum over methods, cut-off points, and
algorithms [immunohistochemistry (IHC) versus fluorescence in
situ hybridization (FISH) as the primary testing assay] [4,5]. The
outcome is a significant percentage of false negative (12%) or false
positive results (14%) [6].
This controversy is also entering the field of NSCLC ALK
testing [7], with an increasing number of recent publications
addressing discordances between in situ hybridization and IHC
assays [8–14], further fuelled by the different regulatory approvals
and the arrival of other ALK inhibitors [3,15]. While some groups
recommend initial IHC followed by FISH confirmation of some
IHC-positive cases [14,16], others believe the detection of ALK
rearrangements is improved when using two methodologies [9,17].
This situation prompted us to investigate two IHC antibodies,
using a novel ultrasensitive detection-amplification kit, and an
automated FISH scanning system in a series of tumor samples to
obtain supporting data for an ALK testing algorithm [18]. To our
knowledge, there has not been an independent assessment of ALK
concordance between these three assays using our strategy (i.e.,




Seventy-nine ALK FISH-positive samples from patients with
advanced NSCLCs procured at 11 hospitals were used for this
study. The Institutional Ethics Committee at Grupo Hospital de
Madrid reviewed and approved this study and waived the need for
consent. Samples were consecutive ALK positive cases, initially
tested as part of routine clinical care. In addition, 77 consecutive
ALK FISH-negative samples from advanced NSCLCs diagnosed
at the referral institution were included as negative controls. The
material available for all tumors had been formalin-fixed and
paraffin-embedded (FFPE). The specifics of formalin fixation were
unknown. All cases were classified by two pathologists (E.C. and
F.L-R.) [19,20]. All specimens were independently screened for
ALK expression by two IHC antibodies, and for ALK rearrange-
ment by FISH, which was scored using an automated scanning
system (FDA-cleared) [21]. Cases were excluded if we could not
score a minimum of 50 nuclei (i.e., gold standard package insert
recommendation, see below). The Institutional Ethics Committee
at the referral institution reviewed and approved this study.
FISH for ALK rearrangement
FISH was performed on unstained 4 mm-thick FFPE tumor
tissue sections using the ALK break-apart probe set (Vysis ALK
FISH break-apart kit; Abbott Molecular, IL, USA), following the
manufacturer’s instructions [22,23]. The ALK FISH assay was
independently captured and scored with the automated BioView
Duet scanning system (BioView, Rehovot, Israel) by two
pathologists blinded to the IHC results (E.C. and A.S-G.). The
system included a fluorescent microscope (Olympus), a high-
resolution progressive-scan charge-coupled device digital camera,
and a computer equipped with imaging and analysis software. The
procedure consisted of the following steps: (1) proper tumour tissue
sections were selected for automated imaging and analysis using a
610 objective to locate the nuclei; (2) the system automatically
captured and analyzed the nuclei found in those regions using a
660 objective with immersion oil and the single band DAPI/
SpectrumGreen/SpectrumOrange filter; and (3) the system
recorded and classified each target nuclei utilizing a specific
algorithm of positive or negative signal patterns based upon the
classifications described in the Vysis ALK FISH break-apart kit
product insert enumeration instructions (also used in the crizotinib
clinical trials). Nuclei that the system could not match to defined
signal patterns were placed in the unclassified category.
A minimum of 50 tumor nuclei were counted. ALK FISH-
positive cases were defined as more than 25 (50%) break-apart
(BA) signals or an isolated signal (IRS) in tumor cells. ALK FISH-
negative samples were defined as less than 5 (10%) BA or IRS
cells. ALK FISH cases were considered borderline if 5–25 (10–
50%) cells were positive. In the case of borderline results, a second
reader evaluated the slide, added cell count readings from the
already automatically captured images, and a percentage was
calculated out of 100 cells. If the positive cells percentage was
lower than 15%, the sample was considered negative. If the
positive cells percentage was higher or equal to 15%, the sample
was considered positive (refer to the package insert for Vysis ALK
Break Apart FISH Probe Kit, Cat. No. 06N38-020/30-608495/
R2).
IHC for ALK expression
Automated IHC for ALK expression was performed for all cases
in a Benchmark XT staining module (Ventana Medical Systems,
Tucson, AZ). FFPE tumor tissues were sectioned at a thickness of
4 mm and stained with two different ALK antibodies: Ventana
anti-ALK rabbit monoclonal primary antibody (Clone D5F3,
Ventana Medical Systems, Tucson, AZ), and Novocastra mouse
monoclonal antibody p80 ALK (Clone 5A4, Novocastra, New-
castle, United Kingdom). Briefly, the Ventana anti-ALK antibody
was applied with OptiView DAB IHC Detection Kit and
OptiView Amplification Kit, performing one serial tissue section
for Ventana anti-ALK (D5F3), and a second serial tissue section
for a Rabbit Monoclonal Negative Control Ig antibody, following
the manufacturer’s instructions. The Novocastra (5A4) antibody
was used at 1:20 dilution, treated, and incubated at 37uC for
2 hours. Detection was performed with the same OptiView
detection-amplification kit. FISH-validated ALK-positive and
ALK-negative external controls were included in all the slides.
The slides were reviewed by two pathologists (E.C. and F.L-R.)
blinded to FISH results. The results of both ALK IHC assays were
evaluated using a modified H-score: strong cytoplasmic staining
(3+), clearly visible using a62 or64 objective; moderate staining
(2+), requiring a610 or620 objective to be clearly seen; and weak
staining (1+), cannot be seen until a 640 objective is used [21].
Both anti-ALK IHC staining results were interpreted using a
binary scoring system: positive (3+ or 2+) or negative (1+ or 0),
adapting to the manufacturer’s instructions [refer to the package
insert for Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary
Antibody, Cat. No. 790-4794/06679072001] and in agreement
with recently released survival data in crizotinib treated patients
[24].
Statistical data analysis
Based on all the valid data obtained, we performed a descriptive
analysis of both the independent and dependent variables of
interest. This analysis was stratified by specimen type, location and
histologic type. The technique used for comparison of frequencies
was Pearson’s x2 test (frequency ,5, Fisher). The normality of the
continuous variables was verified using the Kolmogorov-Smirnov
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test. As these variables, i.e. number of positive cells and number of
negative cells, did not follow a normal distribution, non-
parametric tests were used. For comparison of means we used
the Kruskal-Wallis test. The sensitivity, specificity, and positive
and negative predictive values of the Ventana anti-ALK,
Novocastra (5A4), and FISH using an automated scoring system
were obtained. Statistical differences were deemed significant at p
,0.05. Statistical data analyses were performed using the
Statistical Package for Social Sciences (version 19.0; Chicago,
IL, USA).
Figure 1. Study design and specimen selection.
doi:10.1371/journal.pone.0107200.g001
Figure 2. Immunostaining pattern of ALK in NSCLC using Ventana anti-ALK (D5F3) and Novocastra (5A4) antibodies. ALK IHC reveals
variable levels of protein expression: from absent (0) to weak/faint cytoplasmic staining (1+) in negative cases and from moderate (2+) to strong (3+)
granular cytoplasmic immunstaining in positive tumors. In ALK IHC-negative cases, the immunoreactivity was always 0 by Novocastra (5A4) IHC,
whereas ranged from 0 to 1+ by Ventana antibody. However, in ALK IHC-positive cases, protein expression was always 3+ by Ventana antibody,
whereas it ranged from 2+ to 3+ by Novocastra (5A4) IHC. Original magnification: 4006.
doi:10.1371/journal.pone.0107200.g002
ALK Translocation in Lung Cancer
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Figure 3. Box plots for number of ALK positive cells by FISH automatized technique versus intensity of the ALK IHC staining. With
the Ventana anti-ALK antibody (A) and with Novocastra (5A4) antibody (B). Kruskal-Wallis test was performed. The comparisons between the
categories in each antibody were statistically significant (p,0,001).
doi:10.1371/journal.pone.0107200.g003
ALK Translocation in Lung Cancer
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Results
The results are summarized in Table 1.
ALK rearrangement assessed by FISH
Of the 79 ALK-positive lung carcinoma specimens, 32 cases
were excluded for lack of tumor tissue. Of the 77 ALK-negative
NSCLCs, 21 specimens were excluded for lack of tumor tissue
(Figure 1). Among the 103 available cases analyzed, 47 tumors
(45.6%) had an ALK rearrangement, showing the two major
described patterns [BA pattern in 21.3% of cases (10/47), IRS
pattern in 44.7% of tumors (21/47), and both patterns in 34% of
tumors (16/47)]. Fifty-six (54.4%) cases were negative, showing
two fusion signals or very close green and red signals. The total
number of tumor cells analyzed was 50 in 98 cases (95.1%) and
100 in 5 specimens (4.9%) (cases with initial borderline results). In
ALK FISH-negative cases, the mean percentage of positive cancer
cells was 0.7% (median 0%; range 0 to 6%). In ALK FISH-positive
tumors, the mean percentage of positive cells was 68.2% (median
68%; range 25 to 94%). In three of these ALK-rearranged cases,
the percentage of positive cells was less than 50% (25%, 36% and
46%, respectively). Among FISH ALK-positive cases, we observed
5 tumors (10.6%) with ALK amplification, as previously described
[25].
Correlation between ALK IHC and ALK FISH data
All cases with IHC scores of 3+ (strong cytoplasmic staining) by
Ventana anti-ALK antibody, and all cases with IHC scores of 2+
and 3+ by Novocastra (5A4) antibody (ALK IHC-positive cases)
were FISH-positive. All cases but one with IHC scores of 1+ and 0
by Ventana, and with IHC scores of 0 by Novocastra (ALK IHC-
negative cases) were FISH-negative (Figure 2). There was only one
IHC-negative case with both antibodies which showed a FISH-
positive result (IRS-rearranged pattern in an average of 84% of
tumor cells). Additional blocks were requested and re-tested with
identical results (data not shown). Interestingly, it was a surgically
resected (lobectomy), poorly differentiated squamous cell carcino-
ma (SCC) (i.e., p40 positive by IHC, data not shown). Given the
discrepancy, all results were independently reviewed (F.L-R.) and
confirmed.
ALK immunoreactivity by IHC
Following the above criteria, among the 103 available cases
analyzed, 46 cases (44.7%) were positive, whereas 57 tumors
(55.3%) were negative by both Ventana anti-ALK and Novocastra
(5A4) antibodies. Interestingly, in ALK IHC-negative cases, the
immunoreactivity was always absent (0) by Novocastra (5A4) IHC,
whereas it ranged from absent to weak/faint cytoplasmic staining
(1+) by Ventana antibody. However, in ALK IHC-positive cases,
protein expression was always strong cytoplasmic staining (3+) by
Ventana anti-ALK antibody, whereas it ranged from moderate (2+
) (n = 5) to strong staining (3+) (n = 41) by Novocastra (5A4) IHC
(Figure 2). In 15 positive cases (32.6%) by Ventana IHC and 16
positive tumors (34.8%) by Novocastra IHC, we noted significant
intratumoral heterogeneity, ranging from weak to strong protein
expression.
We evaluated the correlation between IHC staining intensity
and the number of positive cells by FISH. Increases in the staining
intensity by both antibodies were associated with increases in the
number of FISH ALK-rearranged cells (p,0.001): a staining
intensity of 3+ by Ventana IHC resulted in an average of 36.3%
FISH ALK-positive cells, and a staining intensity of 2+ and 3+ by
Novocastra IHC resulted in an average of 31% and 36.9% FISH
ALK-positive cells, respectively (Figure 3).
Sensitivity and specificity of ALK IHC and ALK FISH
The overall sensitivity and specificity of the IHC in comparison
with FISH were 98% and 100%, respectively. The positive and
negative predictive value of the IHC was 100% and 98%,
respectively.
Correlation between ALK rearrangements and
histological data
Among the 47 FISH ALK-positive cases, 26 (55.3%) were
diagnosed as primary lung origin whereas 21 (44.7%) were
metastases from different sites. Of all these samples, nine were
bronchoscopic biopsies (19.1%), two core-needle biopsies (4.3%),
two cell blocks (4.3%), and 34 surgical resections (72.3%).
Interestingly, 50% of the latter were excisions of metastases
(n = 17): soft-tissue (n = 10), lymph nodes (n = 6) and ovary (n = 1).
Pathological characteristics of the ALK-positive tumors were as
follows: 43 (91.5%) adenocarcinomas (ACs), one (2.1%) SCC, and
three (6.4%) NSCLCs NOS. Among the ACs, a predominant solid
and cribiform pattern was observed in 28 out of 43 (65.1%); 11
(25.6%) cases presented acinar architecture; and four (9.3%) a
predominant papillary pattern. Signet ring cells were observed in
21 of 43 (48.8%) positive cases, as previously described [26–28].
Discussion
We have studied one of the largest series of ALK positive tumors
to date. A review of published reports identifies very few larger
series of such tumors investigated by more than one methodology,
and two of those correspond to surgically treated early stage
tumors [11,24,27,29–32]. We find that both IHC and FISH are
reasonable approaches for primary routine ALK testing, provided
that samples have at least 50 informative tumor cells. This is the
number of tumor cells that are required for the FDA-approved
FISH ALK assay. Using this selection criterion, all but one of the
FISH positive cases were confirmed with both IHC antibodies.
Interestingly, this single IHC false negative result occurred in a
patient with a bona fide SCC (i.e., lobectomy with a p40 positive
tumor by IHC) that had a partial response to crizotinib (data not
shown). Although the ALK translocation may be found in pure
squamous carcinoma of the lung (such as the one reported herein),
the role of ALK inhibitors in this setting is still controversial [33].
Interestingly, in a recently reported crizotinib phase 3 trial, a very
small group of non-adenocarcinoma patients had a remarkable
progression-free survival [34]. Taking into consideration the
difficulties in determining histologic subtype in small NSCLC
biopsies, at present it seems unrealistic to have different ALK
testing algorithms driven by histology [35]. Nevertheless, histology
should always be considered since aberrant ALK expression (i.e.,
rearrangement negative) has been described in neuroendocrine
lung carcinomas [17,36].
Although the true reason for the discrepancy outlined above
remains unclear, there are two main possible explanations: (a)
biological, ALK variant-related [12] or due to heterogeneity of
staining, as this situation has been reported specially in SCC and
adenosquamous carcinoma [13,37]; and, (b) methodological, due
to suboptimal pre-analytical or analytical phases as less sensitive
detection systems may result in heterogeneous staining patterns
[18]. In this regard, FISH is less affected by the unavoidable
variability of the pre-analytical phase in pathology laboratories
worldwide, as long as buffered formalin is used as the fixative.
Along these lines, there is always a risk of IHC false negatives due
to the lack of an in situ performance control, as opposed to FISH.
External positive controls should not be used to distinguish a
negative result from a false-negative result caused by uncontrolled
ALK Translocation in Lung Cancer
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pre-analytical parameters. An interesting comparison can be made
with polymerase chain reaction controls. In this methodology,
positive control, negative control, water control (equivalent to the
negative control in the Ventana assay) and inhibition control or
housekeeping gene control (which is lacking in the ALK IHC
assays) should be used. Accordingly, we believe that ideally all IHC
negative cases should be confirmed by FISH. One may still argue
that a single false negative sample is insufficient for this
recommendation. However, a careful review of previous studies
suggests that our experience is not unique [9,13,17,29,32,38–43].
Remarkably, in some of these studies ALK testing was part of
routine clinical care, as in our series. A very recent two-site
comparison shows around 30% of FISH positive-IHC negative
cases [29]. If using this ultrasensitive IHC approach as a screening
tool, a practical recommendation would be to confirm by FISH at
least some of the negative IHC results (for example, samples with
uncontrolled pre-analytical parameters or with higher probability
of harboring ALK translocations).
Conversely, the specificity of these ultrasensitive IHC assays
[14] obviates the need for FISH confirmation in positive IHC
cases. In fact, there have been reports of dramatic responses to
crizotinib in patients with IHC positive and FISH negative tumors
[44]. From a practical point of view, it is important to bear in mind
that in many regions of the world the use of ALK inhibitors may
not be linked to a specific methodology [2]. Taking into
consideration the use of improved IHC protocols, eventual false-
positive IHC results are more likely to be an interpretative error
rather than a technical error, as has been the case in breast HER2
testing [45]. Because dichotomous scoring has been shown to
enhance reproducibility, we must insist in defining such criteria for
each clone. For 5A4, any immunostaining was scored as positive.
For Ventana, only weak cytoplasmic staining was considered
negative (Figure 2). However, several issues may preclude the use
of IHC as a final predictive test. Firstly, the common perception
that IHC should be used as a screening test, followed by
confirmation of the positive cases with the gold-standard method.
The proposed algorithm for the use of mutation-specific EGFR
IHC has been a step forward for this change of paradigm [46].
Secondly, there is a lack of inter-laboratory and inter-observer
uniformity in assay performance and assay interpretation. In this
regard, the standardization of the Ventana assay, from both the
analytical and post-analytical point of view, can help implement
this strategy. Our results with the Novocastra antibody and the
ultrasensitive IHC protocol are very similar to those of other
groups [47].
Finally, it must be emphasized that we (E.C, unpublished data)
and others [14,48,49] have found positive ALK IHC particularly
useful in limited samples or when FISH is not evaluable. However,
a broadly held consensus on the number of positive cells required
for an IHC positive score has yet to emerge. Indeed, it has been
shown that, when less than 50 tumor cells are present, there is a
risk for false-negative IHC results [9]. Accordingly, the number of
IHC positive cells has been compared with staining intensity, for
example, a staining intensity of 2+ required 58.2% of positively
stained cells [50]. The significant correlation that we found when
we compared the number of FISH positive cells and the IHC
intensity further supports the validity of our data.
Due to a series of factors which often coexist, it is difficult to
apply the findings of ALK testing published in the literature to the
clinical reality. Outside of clinical trials or referral testing
laboratories [29,34,51], most series mainly test surgically resected
specimens or tissue microarrays [11–13,16,27,50,52–59] rather
than small biopsies with intention to treat [9,14,30,31,38,60–62].
Therefore, one of the strengths of this study is that this large cohort
of ALK positive samples was initially tested with intention to treat.
However, the fact that over 72% of the samples were ‘‘large’’
specimens (50% of them surgically resected metastases) is a minor
limitation of our series and may not represent routine clinical
practice. Moreover, we had very few cytology samples which are
the most common form of diagnostic material in many institutions.
Although recently released guidelines [35] recommend the use of
cell blocks, excellent results have been reported for both IHC and
FISH with stained smears and liquid-based preparations
[14,38,63]. Another potential caveat of our work is that this is a
retrospective series and we cannot comment on the performance
of the assays in predicting response to ALK inhibition. To partially
overcome this shortcoming, we decided to increase the robustness
of the gold standard. Reasoning that the ALK FISH assay is
especially difficult to interpret and prone to both false-negatives
and false-positives [9,14,32,38,49,59,64], we used an outstanding
automated FISH scanning system that has recently received FDA-
clearance. This strategy provided fast automated scanning, which
reduced overall scoring and reporting time, provided standardi-
zation of the FISH signal interpretation and ensured sensitive
counting.
In summary, we find that IHC and FISH techniques are
optimal for the detection of ALK translocations in NSCLC
patients if at least 50 tumor cells are scored and protocols are
strictly followed. The interpretative stringency provided by using
negative controls and knowledge of interpretation patterns can
avoid IHC false positive cases. The real-world likelihood of false
negative IHC results, whether biological or methodological,
strengthens the case for FISH confirmation, at least in some
situations (for example, in samples with uncontrolled pre-analytical
parameters or with higher probability of harboring ALK
translocations). A consideration of the clinical problem of NSCLC
highlights the need to be aware of how the methods that we use
perform in reality.
Acknowledgments
F. Lo´pez-Rı´os thanks R. Franklin for her contribution to this work. The
authors wish to thank the Tumor Bank at the ‘Laboratorio de Dianas
Terape´uticas’, Hospital Universitario Sanchinarro, for handling the
samples used in this study, and Dr. Lukas Bubendorf (Basel) for his help
with the immunohistochemistry protocols. The excellent technical help of
Luna Mun˜oz is also gratefully acknowledged. Translated into English by
Michelle Homden.
Author Contributions
Conceived and designed the experiments: EC FL-R. Performed the
experiments: EC FL-R AS-G. Analyzed the data: EC AS-G AB PG RG-C
MB LP-A DH JC MCC DR-A IA JR NR MS LP EA JS VF NV JG-R MH
FL-R. Contributed reagents/materials/analysis tools: EC AS-G AB PG
RG-C MB LP-A DH JC MCC DR-A IA JR NR MS LP EA JS VF NV JG-
R MH FL-R. Wrote the paper: EC AS-G AB PG RG-C MB LP-A DH JC
MCC DR-A IA JR NR MS LP EA JS VF NV JG-R MH FL-R.
References
1. Riely GJ, Chaft JE, Ladanyi M, Kris MG (2011) Incorporation of crizotinib into
de NCCN guidelines. J Natl Compr Can Netw 9: 1328–1330.
2. European Medicines Agency. Available: http://www.ema.europa.eu/docs/en_
GB/document_library/EPAR__Public_assessment_report/human/002489/
WC500134761.pdf. Accessed 2013 July 21.
ALK Translocation in Lung Cancer
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e107200
3. Gridelli C, Solange P, Sgambato A, Casaluce F, Adjei AA, et al. (2014) ALK
inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 40: 300–
306.
4. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, et al. (2013)
Recommendations for human epidermal growth factor receptor 2 testing in
breast cancer: American Society of Clinical Oncology/College of American
Pathologists clinical practice guideline update. J Clin Oncol 31: 3997–4013.
5. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human
epidermal growth factor receptor 2 testing: biologic and methodologic
considerations. J Clin Oncol 27: 1323–1333.
6. De P, Smith BR, Leyland-Jones B (2010) Human epidermal growth factor
receptor 2 testing: where are we? J Clin Oncol 28: 4289–4292.
7. Karachaliou N, Rosell R (2013) Optimal detection of ALK rearranged lung
adenocarcinomas. J Thorac Oncol 8: 255–256.
8. Kim H, Xu X, Yoo SB, Sun PL, Jin Y, et al. (2013) Discordance between
anaplastic lymphoma kinase status in primary non-small-cell lung cancers and
their corresponding metastases. Histopathology 62: 305–314.
9. Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, et al. (2013)
Combined use of ALK immunohistochemistry and FISH for optimal detection
of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 8: 322–328.
10. Han XH, Zhang NN, Ma L, Lin DM, Hao XZ, et al. (2013) Immunohisto-
chemistry reliably detects ALK rearrangements in patients with advanced non-
small-cell lung cancer. Virchows Arch 463: 583–591.
11. Ying J, Guo L, Qiu T, Shan L, Ling Y, et al. (2013) Diagnostic value of a novel
fully automated immunochemistry assay for detection of ALK rearrangement in
primary lung adenocarcinoma. Ann Oncol 24: 2589–2593.
12. Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, et al. (2013) Comparison of
IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in
312 Non-Small Cell Lung Cancer Patients in Taiwan. PLoS One 8: e70839.
13. Li Y, Pan Y, Wang R, Sun Y, Hu H, et al. (2013) ALK-Rearranged Lung
Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC,
FISH and RT-PCR. PLoS One 8: e69016.
14. Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, et al. (2013) ALK status
testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC
and FISH. J Mol Diagn 15: 341–346.
15. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, et al. (2014) Ceritinib in ALK-
rearranged non-small-cell lung cancer. N Engl J Med 370: 1189–1197.
16. Takamochi K, Takeuchi K, Hayashi T, Oh S, Suzuki K (2013) A Rational
Diagnostic Algorithm for the Identification of ALK Rearrangement in Lung
Cancer: A Comprehensive Study of Surgically Treated Japanese Patients. PLoS
One 8: e69794.
17. Murakami Y, Mitsudomi T, Yatabe Y (2012) A Screening Method for the ALK
Fusion Gene in NSCLC. Front Oncol 2: 1–9.
18. Nitta H, Tsuta K, Yoshida A, Ho SN, Kelly BD, et al. (2013) New Methods for
ALK Status Diagnosis in Non-Small-Cell Lung Cancer: An Improved ALK
Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC-In Situ
Hybridization Assay. J Thorac Oncol 8: 1019–1031.
19. Travis WD, Brambilla E, Mu¨ller-Hermelink HK, Curtis CH (2004) WHO
Classification. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus
and Heart. Lyon: IARC Press.
20. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al.
(2011) International Association for the Study of Lung Cancer/American
Thoracic Society/European Respiratory Society international multidisciplinary
classification of lung adenocarcinoma. J Thorac Oncol 6: 244–285.
21. BioView. Available: http://www.bioview.co.il/HTMLs/page_70.aspx?c0=
12677&bsp=12624&bss53=12640. Accessed 2014 May 14.
22. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, et al. (2012)
EML4-ALK testing in non-small cell carcinomas of the lung: a review with
recommendations. Virchows Arch 461: 245–257.
23. Conde E, Angulo B, Izquierdo E, Mun˜oz L, Sua´rez-Gauthier A, et al. (2013)
The ALK translocation in advanced non-small-cell lung carcinomas: pre-
approval testing experience at a single cancer centre. Histopathology 62: 609–
616.
24. Zhang NN, Liu YT, Ma L, Wang L, Hao XZ, et al. (2014) The molecular
detection and clinical significance of ALK rearrangement in selected advanced
non-small cell lung cancer: ALK expression provides insights into ALK targeted
therapy. PLoS One 9: e84501.
25. Salido M, Pijuan L, Martı´nez-Avile´s L, Galva´n AB, Can˜adas I, et al. (2011)
Increased ALK gene copy number and amplification are frequent in non-small
cell lung cancer. J Thorac Oncol 6: 21–27.
26. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique
clinicopathologic features characterize ALK-rearranged lung adenocarcinoma
in the western population. Clin Cancer Res 15: 5216–5223.
27. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, et al. (2011)
Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
Am J Surg Pathol 35: 1226–1234.
28. Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, et al.
(2012) Histologic and cytomorphologic features of ALK-rearranged lung
adenocarcinomas. Mod Pathol 25: 1462–1472.
29. Cabillic F, Gros A, Dugay F, Begueret H, Mesturoux L, et al. (2014) Parallel
FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell
Lung Cancers Reveal Major Discordances. J Thorac Oncol 9: 295–306.
30. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, et al. (2013) ALK
rearrangements are mutually exclusive with mutations in EGFR or KRAS: an
analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 19:
4273–4281.
31. Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, et al. (2014) Lung Cancers with
Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses
to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphoryla-
tion. Clin Cancer Res 20: 1383–1392.
32. Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, et al. (2014) An
international interpretation study using the ALK IHC antibody D5F3 and
asensitive detection kit demonstrates high concordance between ALK IHC and
ALK FISH and between evaluators. J Thorac Oncol 9: 631–638.
33. Calio` A, Nottegar A, Gilioli E, Bria E, Pilotto S, et al. (2014) ALK/EML4 fusion
gene may be found in pure squamous carcinoma of the lung. J Thorac Oncol 9:
729–732.
34. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino´ L, et al. (2013) Crizotinib
versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med
368: 2385–2394.
35. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013)
Molecular testing guideline for selection of lung cancer patients for EGFR and
ALK tyrosine kinase inhibitors: guideline from the College of American
Pathologists, International Association for the Study of Lung Cancer, and
Association for Molecular Pathology. Arch Pathol Lab Med 137: 828–860.
36. Nakamura H, Tsuta K, Yoshida A, Shibata T, Wakai S, et al. (2013) Aberrant
anaplastic lymphoma kinase expression in high-grade pulmonary neuroendo-
crine carcinoma. J Clin Pathol 66: 705–706.
37. Takeuchi K (2013) Interpretation of Anti-ALK Immunohistochemistry Results.
J Thorac Oncol 8: e67–e68.
38. Savic S, Bode B, Diebold J, Tosoni I, Barascud A, et al. (2013) Detection of
ALK-Positive Non-Small-Cell Lung Cancers on Cytological Specimens: High
Accuracy of Immunocytochemistry with the 5A4 Clone. J Thorac Oncol 8:
1004–1011.
39. Martinez P, Herna´ndez-Losa J, Montero MA´, Cedre´s S, Castellvı´ J, et al. (2013)
Fluorescence in situ hybridization and immunohistochemistry as diagnostic
methods for ALK positive non-small cell lung cancer patients. PLoS One 8:
e52261.
40. Blackhall FH, Peters S, Kerr KM, O9Byrne KJ, Hager H, et al. (2012)
Prevalence and clinical outcomes for patients with ALK positive adenocarcino-
ma in Europe: preliminary results from the European Thoracic Oncology
Platform Lungscape Project. ESMO.
41. Le Quesne J, Maurya M, Yancheva SG, O9Brien M, Popat S, et al. (2014) A
Comparison of Immunohistochemical Assays and FISH in Detecting the ALK
Translocation in Diagnostic Histological and Cytological Lung Tumor Material.
J Thorac Oncol 9: 769–74.
42. Demidova I, Barinov A, Savelov N, Gagarin I, Grinevitch V, et al. (2014)
Immunohistochemistry, fluorescence in situ hybridization, and reverse tran-
scription-polymerase chain reaction for the detection of anaplastic lymphoma
kinase gene rearrangements in patients with non-small cell lung cancer: potential
advantages and methodologic pitfalls. Arch Pathol Lab Med 138: 794–802.
43. Alı` G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, et al. (2014) ALK
Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers:
Comparison Between a New Immunohistochemical Approach and Fluorescent
In Situ Hybridization for the Screening of Patients Eligible for Crizotinib
Treatment. Arch Pathol Lab Med Jun 2. [Epub ahead of print] PubMed PMID:
24885803.
44. Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, et al. (2012). A dramatic
response to crizotinib in a non-small-cell lung cancer patient with IHC-positive
and FISH-negative ALK. J Thorac Oncol 7: e36–38.
45. Grimm EE, Schmidt RA, Swanson PE, Dintzis SM, Allison KH (2010)
Achieving 95% cross-methodological concordance in HER2 testing: causes and
implications of discordant cases. Am J Clin Pathol 134: 284–292.
46. Brevet M, Arcila M, Ladanyi M (2010) Assessment of EGFR mutation status in
lung adenocarcinoma by immunohistochemistry using antibodies specific to the
two major forms of mutant EGFR. J Mol Diagn 12: 169–176.
47. Tuononen K, Sarhadi VK, Wirtanen A, Ro¨nty M, Salmenkivi K, et al. (2013)
Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas
detected by FISH, immunohistochemistry, and real-time RT-PCR: a compar-
ison of four methods. Biomed Res Int 757490.
48. Dacic S (2013) Molecular genetic testing for lung adenocarcinomas: a practical
approach to clinically relevant mutations and translocations. J Clin Pathol 66:
870–874.
49. Zhou J, Zhao J, Sun K, Wang B, Wang L, et al. (2014) Accurate and economical
detection of ALK positive lung adenocarcinoma with semiquantitative
immunohistochemical screening. PLoS One 9: e92828.
50. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, et al. (2011) Screening of anaplastic
lymphoma kinase rearrangement by immunohistochemistry in non-small cell
lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol
6: 466–672.
51. McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, et al.
(2012) Dual IHC and FISH testing for ALK gene rearrangement in lung
adenocarcinomas in a routine practice: a French study. J Thorac Oncol 7: 348–
354.
52. Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, et al. (2012)
Clinicoradiologic characteristics of patients with lung adenocarcinoma harbor-
ing EML4-ALK fusion oncogene. Lung Cancer 77: 319–325.
ALK Translocation in Lung Cancer
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e107200
53. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, et al. (2012) Clinicopathologic
implication of ALK rearrangement in surgically resected lung cancer: A proposal
of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 76:
403–409.
54. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. (2009) The EML4-
ALK fusion gene is involved in various histologic types of lung cancers from
nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723–1733.
55. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, et al. (2009)
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1
cell lineage, an acinar histology, and young onset. Mod Pathol 22: 508–515.
56. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, et al. (2013)
Immunohistochemistry is a reliable screening tool for identification of ALK
rearrangement in non-small-cell lung carcinoma and is antibody dependent.
J Thorac Oncol 8: 45–51.
57. Selinger CI, Rogers TM, Russell PA, O9Toole S, Yip P et al. (2013) Testing for
ALK rearrangement in lung adenocarcinoma: a multicenter comparison of
immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 26:
1545–1553.
58. V Laffert M, Warth A, Penzel R, Schirmacher P, Jonigk D, et al. (2013)
Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung
cancer (NSCLC): Results of a multi-centre ALK-testing. Lung Cancer 81: 200–
206.
59. To KF, Tong JH, Yeung KS, Lung RW, Law PP et al. (2013) Detection of ALK
Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the
Identification of a Novel EML4-ALK Variant. J Thorac Oncol 8: 883–891.
60. Li T, Maus MK, Desai SJ, Beckett LA, Stephens C, et al. (2014) Large-scale
screening and molecular characterization of EML4-ALK fusion variants in
archival non-small-cell lung cancer tumor specimens using quantitative reverse
transcription polymerase chain reaction assays. J Thorac Oncol 9: 18–25.
61. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, et al. (2013)
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-
small cell lung cancer. Ann Oncol 24: 59–66.
62. Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, et al. (2013) Native
and rearranged ALK copy number and rearranged cell count in non-small cell
lung cancer: Implications for ALK inhibitor therapy. Cancer 119: 3968–3975.
63. Proietti A, Alı` G, Pelliccioni S, Lupi C, Sensi E, et al. (2014) Anaplastic
lymphoma kinase gene rearrangements in cytological samples of non-small cell
lung cancer: Comparison with histological assessment. Cancer Cytopathol. 122:
445–453.
64. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ (2012) Comparison of
reverse transcription-polymerase chain reaction, immunohistochemistry, and
fluorescence in situ hybridization methodologies for detection of echinoderm
microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive
non-small cell lung carcinoma: implications for optimal clinical testing. Arch
Pathol Lab Med 136: 796–803.
ALK Translocation in Lung Cancer
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e107200
